Wellington Management Group
ACRV icon

Wellington Management Group’s Acrivon Therapeutics ACRV Stock Holding History

Wellington Management Group’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Hold
888,130
– – ﹤0.01% 1639
2025
Q4 		$2.14M Hold
888,130
– – ﹤0.01% 1585
2025
Q3 		$1.61M Hold
888,130
– – ﹤0.01% 1687
2025
Q2 		$1.06M Hold
888,130
– – ﹤0.01% 1713
2025
Q1 		$1.8M Hold
888,130
– – ﹤0.01% 1585
2024
Q4 		$5.35M Hold
888,130
– – ﹤0.01% 1338
2024
Q3 		$6.22M Hold
888,130
– – ﹤0.01% 1278
2024
Q2 		$5.15M Hold
888,130
– – ﹤0.01% 1317
2024
Q1 		$6.35M Hold
888,130
– – ﹤0.01% 1274
2023
Q4 		$4.37M Hold
888,130
– – ﹤0.01% 1340
2023
Q3 		$8.49M Hold
888,130
– – ﹤0.01% 1148
2023
Q2 		$11.5M Hold
888,130
– – ﹤0.01% 1071
2023
Q1 		$11.1M Sell
888,130
-12,019
-1% -$202K ﹤0.01% 1074
2022
Q4 		$9.99M Buy
+900,149
New +$11.4M ﹤0.01% 1087

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group's ACRV Position: Q1 2026 in Review

Wellington Management Group held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 888,130 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Wellington Management Group first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $11.5M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Wellington Management Group held 888,130 shares of Acrivon Therapeutics worth $1.23M as of Q1 2026.
  • Wellington Management Group left its Acrivon Therapeutics share count unchanged in Q1 2026.
  • Acrivon Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1639 holding.
  • Wellington Management Group first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Wellington Management Group's Acrivon Therapeutics position peaked at $11.5M in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.